Results 31 to 40 of about 1,506 (115)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

npj Precision Oncology, 2021
Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown.
Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu   +5 more
doaj   +1 more source

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

Frontiers in Oncology, 2022
We are recently faced with a progressive evolution of the therapeutic paradigm for radioiodine refractory differentiated thyroid cancer (RAI-R DTC), since the advent of tissue agnostic inhibitors.
Margherita Nannini, Margherita Nannini, Andrea Repaci, Gianluca Ricco, Manuela Ianni, Arber Golemi, Vincenzo Maiolo, Marco Ferrari, Filippo Natali, Elisa Lodi Rizzini, Fabio Monari, Erica Solaroli, Antonio De Leo, Antonio De Leo, Thais Maloberti, Maria A. Pantaleo, Maria A. Pantaleo, Dario De Biase, Dario De Biase, Giovanni Tallini, Giovanni Tallini   +20 more
doaj   +1 more source

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

Frontiers in Oncology, 2022
RET rearrangements are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. Pralsetinib has a significant anti-tumor effect in patients with advanced NSCLC and a RET rearrangement. Previous studies have confirmed the efficiency of
Ning Zhou, Ning Zhou, Tong Li, Tong Li, Maoli Liang, Fan Ren, Fan Ren, Hong Ni, Hong Ni, Wei Liu, Tao Shi, Dongbo Xu, Qiusong Chen, Haonan Yu, Zuoqing Song, Zuoqing Song, Lingling Zu, Lingling Zu, Shuo Li, Song Xu, Song Xu   +20 more
doaj   +1 more source

Pralsetinib: A Drug Review

Indian Journal of Medical and Paediatric Oncology
REarranged during Transfection (RET) is a transforming proto-oncogene that codes for the tyrosine kinase receptor. Pralsetinib is an orally bioavailable, selective inhibitor of mutant forms and fusions involving the RET proto-oncogene.
Abha Deshpande, Ryan Varghese, Jainam Karsiya, Praveen Jha, Padmaj Kulkarni   +4 more
doaj   +1 more source

Precision oncology for RET-related tumors

Frontiers in Oncology, 2022
Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) syndrome and in sporadic medullary thyroid cancer, while RET ...
Antonella Verrienti, Giorgio Grani, Marialuisa Sponziello, Valeria Pecce, Giuseppe Damante, Cosimo Durante, Diego Russo, Sebastiano Filetti   +7 more
doaj   +1 more source

Precious Gene: The Application of RET-Altered Inhibitors

Molecules, 2022
The well-known proto-oncogene rearrangement during transfection (RET), also known as ret proto-oncogene Homo sapiens (human), is a rare gene that is involved in the physiological development of some organ systems and can activate various cancers, such as
Qitao Gou, Xiaochuan Gan, Longhao Li, Qiheng Gou, Tao Zhang   +4 more
doaj   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug

Frontiers in Chemistry
BackgroundPralsetinib, a targeted inhibitor of the RET enzyme, plays a critical role in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by RET gene fusion mutations following platinum ...
Yonghong Zhu, Jisu Qin, Wenyi Wu, Liangliang Cai   +3 more
doaj   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations

Clinical and Translational Science
A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in 15 healthy adult volunteers.
Julia Suchomel, Priya Agarwal, Doreen Anders, Kevin Hughes, Yang Tang, Rucha Sane, Astrid Scalori, Sunil Sharma, Sravanthi Cheeti   +8 more
doaj   +1 more source